구조모아 (StructureMoa)항암 chemical structure spider web
방문향후 6개월 내 primary completion 예정인 활성 임상과 큐레이션·승인 프로그램의 phase 분포입니다. CT.gov completion date 기반 추정이며 공식 readout 일정과 다를 수 있습니다. RSS
큐레이션·FDA·임상 3건 이상 프로그램 2029개 — catalyst 일정과 별도의 전체 파이프라인 스냅샷입니다.
향후 6개월 catalyst 26건 · 타깃·모달리티 분포
활성 recruiting/enrolling 임상 · CT.gov completion 기준 · 상위 80건 표시
| 완료 예정 | 프로그램 | Phase | Status | Endpoint | 신뢰도 | NCT |
|---|---|---|---|---|---|---|
| 2026년 9월 | Ramucirumab | Phase 3 | Recruiting | Progression Free Survival (PFS) in all randomized participants; Overall Survival (OS) for 3L+ participants | 신뢰 높음 | NCT06346392 |
| 2026년 9월 | Ipilimumab | Phase 1 | Active, not recruiting | Incidence of adverse events of entinostat and nivolumab in combination with ipilimumab | 신뢰 높음 | NCT02453620 |
| 2026년 9월 | Tecentriq (atezolizumab) | Phase 1 | Active, not recruiting | Feasibility of Neoadjuvant Cisplatin-Pemetrexed-Atezolizumab, Surgery +/- Radiation, and Maintenance Therapy.; Safety of Neoadjuvant Cisplatin-Pemetrexed-Atezolizumab, Surgery +/- Radiation, and Maintenance Therapy. | 보통 | NCT03228537 |
| 2026년 9월 | Herceptin (trastuzumab) | Phase 2 | Active, not recruiting | Response to Neoadjuvant Chemotherapy Determined at Surgery (Lumpectomy or Mastectomy). | 보통 | NCT02827877 |
| 2026년 9월 | Ipilimumab | Phase 1 | Active, not recruiting | Incidence of adverse events; Dose-limiting toxicity (DLT); Feasibility (neoadjuvant therapy); Feasibility (adjuvant therapy); Overall Survival | 보통 | NCT04003649 |
| 2026년 9월 | Keytruda (pembrolizumab) | Phase 3 | Active, not recruiting | Progression-free Survival (PFS) | 신뢰 높음 | NCT03914612 |
| 2026년 9월 | Keytruda (pembrolizumab) | N/A | Active, not recruiting | Central and local clinical genotyping to facilitate accrual to the adjuvant Intergroup studies, E4512 and A081105; Feasibility of research grade formalin-fixed, paraffin-embedded tissue collection for Center for Cancer Genomics (CCG) analysis | 신뢰 높음 | NCT02194738 |
| 2026년 9월 | Keytruda (pembrolizumab) | Phase 2 | Active, not recruiting | Objective Response Rate as Assessed by Independent Review Committee (IRC) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1; Percentage of Participants Experiencing Dose-limiting Toxicities (DLTs) per Dose Level in the Safety Run-in Cohorts | 신뢰 높음 | NCT05186974 |
| 2026년 9월 | Ipilimumab | Phase 2 | Active, not recruiting | Proportion of patients who have objective tumor response (complete or partial) by modified RECIST 1.1 in patients with clear cell carcinomas treated with nivolumab or the combination of nivolumab and ipilimumab | 보통 | NCT03355976 |
| 2026년 9월 | Padcev (enfortumab vedotin) | N/A | Recruiting | Change from Baseline in Circulating EV Concentration | 신뢰 높음 | NCT07558447 |
| 2026년 9월 | Keytruda (pembrolizumab) | Phase 2 | Active, not recruiting | Pathological Complete Response | 보통 | NCT04869137 |
| 2026년 9월 | Tecentriq (atezolizumab) | Phase 2 | Active, not recruiting | Number of patients who experience complete or partial tumor response | 신뢰 높음 | NCT03526432 |
| 2026년 9월 | Tecentriq (atezolizumab) | Phase 2 | Active, not recruiting | Failure-free Rate at 2 Years | 보통 | NCT04262154 |
| 2026년 9월 | Keytruda (pembrolizumab) | Phase 2 | Recruiting | Proportion of Participants with Progression-Free Survival | 신뢰 높음 | NCT04253964 |
| 2026년 9월 | Ramucirumab | Phase 2 | Recruiting | To estimate overall response rate | 신뢰 높음 | NCT04332367 |
| 2026년 9월 | Vyloy (zolbetuximab) | Phase 3 | Active, not recruiting | Progression Free Survival (PFS) | 신뢰 높음 | NCT03504397 |
| 2026년 9월 | Padcev (enfortumab vedotin) | Phase 2 | Active, not recruiting | Cohorts 1-8: Confirmed Overall Response Rate (ORR) (Complete Response [CR] and Partial Response [PR]) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (V)1.1 Per Investigator Assessment; Cohort 9: Confirmed ORR (CR and PR) Per RECIST V1.1 Per Investigator Assessment | 신뢰 높음 | NCT04225117 |
| 2026년 9월 | Herceptin (trastuzumab) | Phase 2 | Active, not recruiting | Number of Participants With Complete Pathologic Response (pCR) | 신뢰 높음 | NCT03879577 |
| 2026년 9월 | Vyloy (zolbetuximab) | Phase 3 | Active, not recruiting | Progression Free Survival (PFS) | 신뢰 높음 | NCT03653507 |
| 2026년 9월 | Cemiplimab | — | Recruiting | Incidence of treatment-related sexual dysfuction in male patients with ANSCLC | 신뢰 높음 | NCT06532149 |
| 2026년 9월 | Ipilimumab | Phase 1 | Active, not recruiting | Recommended phase II dose (Phase I); Incidence of adverse events (Phase I) | 신뢰 높음 | NCT02496208 |
| 2026년 9월 | Herceptin (trastuzumab) | Phase 2 | Active, not recruiting | Pathological Complete Response rate (pCR) | 신뢰 높음 | NCT04172259 |
| 2026년 9월 | Ivonescimab | Phase 2 | Not yet recruiting | 6-month-PFS rate | 보통 | NCT06991491 |
| 2026년 9월 | Keytruda (pembrolizumab) | Phase 1 | Recruiting | Dose Limiting Toxicity (DLT); Non-Tolerated Dose (NTD); Maximum Tolerated Dose (MTD); Progression Free Survival (PFS) (Randomized Cohort only); Adverse Events (AEs) | 신뢰 높음 | NCT05403554 |
| 2026년 9월 | Obinutuzumab | N/A | Recruiting | Progression-free survival rate at 24 months | 신뢰 높음 | NCT05950997 |
| 2026년 9월 | Keytruda (pembrolizumab) | Phase 1, Phase 2 | Not yet recruiting | safety rate; objective response rate | 보통 | NCT05286320 |
Progression Free Survival (PFS) in all randomized participants; Overall Survival (OS) for 3L+ participants
NCT06346392Incidence of adverse events of entinostat and nivolumab in combination with ipilimumab
NCT02453620Feasibility of Neoadjuvant Cisplatin-Pemetrexed-Atezolizumab, Surgery +/- Radiation, and Maintenance Therapy.; Safety of Neoadjuvant Cisplatin-Pemetrexed-Atezolizumab, Surgery +/- Radiation, and Maintenance Therapy.
NCT03228537Response to Neoadjuvant Chemotherapy Determined at Surgery (Lumpectomy or Mastectomy).
NCT02827877Incidence of adverse events; Dose-limiting toxicity (DLT); Feasibility (neoadjuvant therapy); Feasibility (adjuvant therapy); Overall Survival
NCT04003649Progression-free Survival (PFS)
NCT03914612Central and local clinical genotyping to facilitate accrual to the adjuvant Intergroup studies, E4512 and A081105; Feasibility of research grade formalin-fixed, paraffin-embedded tissue collection for Center for Cancer Genomics (CCG) analysis
NCT02194738Objective Response Rate as Assessed by Independent Review Committee (IRC) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1; Percentage of Participants Experiencing Dose-limiting Toxicities (DLTs) per Dose Level in the Safety Run-in Cohorts
NCT05186974Proportion of patients who have objective tumor response (complete or partial) by modified RECIST 1.1 in patients with clear cell carcinomas treated with nivolumab or the combination of nivolumab and ipilimumab
NCT03355976Change from Baseline in Circulating EV Concentration
NCT07558447Pathological Complete Response
NCT04869137Number of patients who experience complete or partial tumor response
NCT03526432Failure-free Rate at 2 Years
NCT04262154Proportion of Participants with Progression-Free Survival
NCT04253964To estimate overall response rate
NCT04332367Progression Free Survival (PFS)
NCT03504397Cohorts 1-8: Confirmed Overall Response Rate (ORR) (Complete Response [CR] and Partial Response [PR]) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (V)1.1 Per Investigator Assessment; Cohort 9: Confirmed ORR (CR and PR) Per RECIST V1.1 Per Investigator Assessment
NCT04225117Number of Participants With Complete Pathologic Response (pCR)
NCT03879577Progression Free Survival (PFS)
NCT03653507Incidence of treatment-related sexual dysfuction in male patients with ANSCLC
NCT06532149Recommended phase II dose (Phase I); Incidence of adverse events (Phase I)
NCT02496208Pathological Complete Response rate (pCR)
NCT041722596-month-PFS rate
NCT06991491Dose Limiting Toxicity (DLT); Non-Tolerated Dose (NTD); Maximum Tolerated Dose (MTD); Progression Free Survival (PFS) (Randomized Cohort only); Adverse Events (AEs)
NCT05403554Progression-free survival rate at 24 months
NCT05950997safety rate; objective response rate
NCT05286320향후 6개월 내 primary completion 예정인 활성 임상과 큐레이션·승인 프로그램의 phase 분포입니다. CT.gov completion date 기반 추정이며 공식 readout 일정과 다를 수 있습니다. RSS
큐레이션·FDA·임상 3건 이상 프로그램 2029개 — catalyst 일정과 별도의 전체 파이프라인 스냅샷입니다.
향후 6개월 catalyst 26건 · 타깃·모달리티 분포
활성 recruiting/enrolling 임상 · CT.gov completion 기준 · 상위 80건 표시
| 완료 예정 | 프로그램 | Phase | Status | Endpoint | 신뢰도 | NCT |
|---|---|---|---|---|---|---|
| 2026년 9월 | Ramucirumab | Phase 3 | Recruiting | Progression Free Survival (PFS) in all randomized participants; Overall Survival (OS) for 3L+ participants | 신뢰 높음 | NCT06346392 |
| 2026년 9월 | Ipilimumab | Phase 1 | Active, not recruiting | Incidence of adverse events of entinostat and nivolumab in combination with ipilimumab | 신뢰 높음 | NCT02453620 |
| 2026년 9월 | Tecentriq (atezolizumab) | Phase 1 | Active, not recruiting | Feasibility of Neoadjuvant Cisplatin-Pemetrexed-Atezolizumab, Surgery +/- Radiation, and Maintenance Therapy.; Safety of Neoadjuvant Cisplatin-Pemetrexed-Atezolizumab, Surgery +/- Radiation, and Maintenance Therapy. | 보통 | NCT03228537 |
| 2026년 9월 | Herceptin (trastuzumab) | Phase 2 | Active, not recruiting | Response to Neoadjuvant Chemotherapy Determined at Surgery (Lumpectomy or Mastectomy). | 보통 | NCT02827877 |
| 2026년 9월 | Ipilimumab | Phase 1 | Active, not recruiting | Incidence of adverse events; Dose-limiting toxicity (DLT); Feasibility (neoadjuvant therapy); Feasibility (adjuvant therapy); Overall Survival | 보통 | NCT04003649 |
| 2026년 9월 | Keytruda (pembrolizumab) | Phase 3 | Active, not recruiting | Progression-free Survival (PFS) | 신뢰 높음 | NCT03914612 |
| 2026년 9월 | Keytruda (pembrolizumab) | N/A | Active, not recruiting | Central and local clinical genotyping to facilitate accrual to the adjuvant Intergroup studies, E4512 and A081105; Feasibility of research grade formalin-fixed, paraffin-embedded tissue collection for Center for Cancer Genomics (CCG) analysis | 신뢰 높음 | NCT02194738 |
| 2026년 9월 | Keytruda (pembrolizumab) | Phase 2 | Active, not recruiting | Objective Response Rate as Assessed by Independent Review Committee (IRC) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1; Percentage of Participants Experiencing Dose-limiting Toxicities (DLTs) per Dose Level in the Safety Run-in Cohorts | 신뢰 높음 | NCT05186974 |
| 2026년 9월 | Ipilimumab | Phase 2 | Active, not recruiting | Proportion of patients who have objective tumor response (complete or partial) by modified RECIST 1.1 in patients with clear cell carcinomas treated with nivolumab or the combination of nivolumab and ipilimumab | 보통 | NCT03355976 |
| 2026년 9월 | Padcev (enfortumab vedotin) | N/A | Recruiting | Change from Baseline in Circulating EV Concentration | 신뢰 높음 | NCT07558447 |
| 2026년 9월 | Keytruda (pembrolizumab) | Phase 2 | Active, not recruiting | Pathological Complete Response | 보통 | NCT04869137 |
| 2026년 9월 | Tecentriq (atezolizumab) | Phase 2 | Active, not recruiting | Number of patients who experience complete or partial tumor response | 신뢰 높음 | NCT03526432 |
| 2026년 9월 | Tecentriq (atezolizumab) | Phase 2 | Active, not recruiting | Failure-free Rate at 2 Years | 보통 | NCT04262154 |
| 2026년 9월 | Keytruda (pembrolizumab) | Phase 2 | Recruiting | Proportion of Participants with Progression-Free Survival | 신뢰 높음 | NCT04253964 |
| 2026년 9월 | Ramucirumab | Phase 2 | Recruiting | To estimate overall response rate | 신뢰 높음 | NCT04332367 |
| 2026년 9월 | Vyloy (zolbetuximab) | Phase 3 | Active, not recruiting | Progression Free Survival (PFS) | 신뢰 높음 | NCT03504397 |
| 2026년 9월 | Padcev (enfortumab vedotin) | Phase 2 | Active, not recruiting | Cohorts 1-8: Confirmed Overall Response Rate (ORR) (Complete Response [CR] and Partial Response [PR]) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (V)1.1 Per Investigator Assessment; Cohort 9: Confirmed ORR (CR and PR) Per RECIST V1.1 Per Investigator Assessment | 신뢰 높음 | NCT04225117 |
| 2026년 9월 | Herceptin (trastuzumab) | Phase 2 | Active, not recruiting | Number of Participants With Complete Pathologic Response (pCR) | 신뢰 높음 | NCT03879577 |
| 2026년 9월 | Vyloy (zolbetuximab) | Phase 3 | Active, not recruiting | Progression Free Survival (PFS) | 신뢰 높음 | NCT03653507 |
| 2026년 9월 | Cemiplimab | — | Recruiting | Incidence of treatment-related sexual dysfuction in male patients with ANSCLC | 신뢰 높음 | NCT06532149 |
| 2026년 9월 | Ipilimumab | Phase 1 | Active, not recruiting | Recommended phase II dose (Phase I); Incidence of adverse events (Phase I) | 신뢰 높음 | NCT02496208 |
| 2026년 9월 | Herceptin (trastuzumab) | Phase 2 | Active, not recruiting | Pathological Complete Response rate (pCR) | 신뢰 높음 | NCT04172259 |
| 2026년 9월 | Ivonescimab | Phase 2 | Not yet recruiting | 6-month-PFS rate | 보통 | NCT06991491 |
| 2026년 9월 | Keytruda (pembrolizumab) | Phase 1 | Recruiting | Dose Limiting Toxicity (DLT); Non-Tolerated Dose (NTD); Maximum Tolerated Dose (MTD); Progression Free Survival (PFS) (Randomized Cohort only); Adverse Events (AEs) | 신뢰 높음 | NCT05403554 |
| 2026년 9월 | Obinutuzumab | N/A | Recruiting | Progression-free survival rate at 24 months | 신뢰 높음 | NCT05950997 |
| 2026년 9월 | Keytruda (pembrolizumab) | Phase 1, Phase 2 | Not yet recruiting | safety rate; objective response rate | 보통 | NCT05286320 |
Progression Free Survival (PFS) in all randomized participants; Overall Survival (OS) for 3L+ participants
NCT06346392Incidence of adverse events of entinostat and nivolumab in combination with ipilimumab
NCT02453620Feasibility of Neoadjuvant Cisplatin-Pemetrexed-Atezolizumab, Surgery +/- Radiation, and Maintenance Therapy.; Safety of Neoadjuvant Cisplatin-Pemetrexed-Atezolizumab, Surgery +/- Radiation, and Maintenance Therapy.
NCT03228537Response to Neoadjuvant Chemotherapy Determined at Surgery (Lumpectomy or Mastectomy).
NCT02827877Incidence of adverse events; Dose-limiting toxicity (DLT); Feasibility (neoadjuvant therapy); Feasibility (adjuvant therapy); Overall Survival
NCT04003649Progression-free Survival (PFS)
NCT03914612Central and local clinical genotyping to facilitate accrual to the adjuvant Intergroup studies, E4512 and A081105; Feasibility of research grade formalin-fixed, paraffin-embedded tissue collection for Center for Cancer Genomics (CCG) analysis
NCT02194738Objective Response Rate as Assessed by Independent Review Committee (IRC) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1; Percentage of Participants Experiencing Dose-limiting Toxicities (DLTs) per Dose Level in the Safety Run-in Cohorts
NCT05186974Proportion of patients who have objective tumor response (complete or partial) by modified RECIST 1.1 in patients with clear cell carcinomas treated with nivolumab or the combination of nivolumab and ipilimumab
NCT03355976Change from Baseline in Circulating EV Concentration
NCT07558447Pathological Complete Response
NCT04869137Number of patients who experience complete or partial tumor response
NCT03526432Failure-free Rate at 2 Years
NCT04262154Proportion of Participants with Progression-Free Survival
NCT04253964To estimate overall response rate
NCT04332367Progression Free Survival (PFS)
NCT03504397Cohorts 1-8: Confirmed Overall Response Rate (ORR) (Complete Response [CR] and Partial Response [PR]) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (V)1.1 Per Investigator Assessment; Cohort 9: Confirmed ORR (CR and PR) Per RECIST V1.1 Per Investigator Assessment
NCT04225117Number of Participants With Complete Pathologic Response (pCR)
NCT03879577Progression Free Survival (PFS)
NCT03653507Incidence of treatment-related sexual dysfuction in male patients with ANSCLC
NCT06532149Recommended phase II dose (Phase I); Incidence of adverse events (Phase I)
NCT02496208Pathological Complete Response rate (pCR)
NCT041722596-month-PFS rate
NCT06991491Dose Limiting Toxicity (DLT); Non-Tolerated Dose (NTD); Maximum Tolerated Dose (MTD); Progression Free Survival (PFS) (Randomized Cohort only); Adverse Events (AEs)
NCT05403554Progression-free survival rate at 24 months
NCT05950997safety rate; objective response rate
NCT05286320